About this trial
This clinical trial studies whether Acceptance and Commitment Therapy can be used to help improve cancer distress for patients with hepatobiliary or breast cancers for which no treatment is currently available (incurable). Patients with hepatobiliary cancer (HBC) and breast cancer often experience high levels of distress and reductions in quality of life. Acceptance and Commitment Therapy for incurable cancers (ACT-C) is a behavioral intervention tailored to patients with incurable HBC and breast cancer. It helps patients cope with difficult thoughts and emotions while staying connected to what matters most in life, which may be an effective way to improve cancer distress.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Incurable HBC and breast cancer diagnosis
Age >= 18 years
Able to provide written informed consent
Verbally endorse cancer distress
Disqualifiers
Other psychological therapy that started =< 2 months prior to prospective enrollment
Inability to actively participate in and learn from group therapy (e.g., active/uncontrolled psychotic symptoms, neurological condition, personality pathology) as determined by clinical judgement in Behavioral Medicine Program (BMP) consultation. Individual therapy or alternative group therapy will be offered to patients ineligible per this criterion
Cancer remission
Trial design
Single group
Treatments tested in this trial
Acceptance and Commitment Therapy
BehavioralAttend ACT-C telehealth group sessions
Questionnaire Administration
Other interventionAncillary studies
Telemedicine
Other interventionAttend ACT-C telehealth group sessions
Treatment groups
Trial outcomes
Primary outcomes
Patient satisfaction
The Institute for Healthcare Improvement 10-point Likert scale (0-10) asks: "Would you recommend this program to your friends and family?" A score ≥ 7 indicates high individual satisfaction. Program satisfaction is achieved if 50% of individuals meet this cut-off.
Patient session attendance (Feasibility)
Feasibility will be determined by the number of patients attending ≥ 4 sessions.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.